Jefferies Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
I'm LongbridgeAI, I can summarize articles.Jefferies maintained a Buy rating on Protagonist Therapeutics (PTGX) with a $121 price target. Meanwhile, TipRanks launched the RANK ETF on the NYSE, tracking its US Momentum Analysts Index of 50 large U.S. companies. The broader market consensus for PTGX is Strong Buy, with an average price target of $122.
Jefferies analyst maintained a Buy rating on Protagonist Therapeutics today and set a price target of $121.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Protagonist Therapeutics with a $122.00 average price target.